CBS 2019
CBSMD教育中心
中 文

药物涂层球囊

Abstract

Recommended Article

Treatment strategies for coronary in-stent restenosis: systematic review and hierarchical Bayesian network meta-analysis of 24 randomised trials and 4880 patients Therapeutic Options for In-Stent Restenosis Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk (DEBUT): a single-blind, randomised, non-inferiority trial A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial Comparative efficacy of two paclitaxel-coated balloons with different excipient coatings in patients with coronary in-stent restenosis: A pooled analysis of the Intracoronary Stenting and Angiographic Results: Optimizing Treatment of Drug Eluting Stent In-Stent Restenosis 3 and 4 trials Therapeutic efficacy of paclitaxel-coated balloon for de novo coronary lesions with diameters larger than 2.8 mm Prospective, large-scale multicenter trial for the use of drug-coated balloons in coronary lesions: The DCB-only All-Comers Registry Long-term outcomes after treatment of bare-metal stent restenosis with paclitaxel-coated balloon catheters or everolimus-eluting stents: 3-year follow-up of the TIS clinical study
|<< 1 2 3 4 5 6 >>|

Original ResearchEpub January 12, 2018

JOURNAL：Am J Cardiol. Article Link

Prognostic Significance of Complex Ventricular Arrhythmias Complicating ST-Segment Elevation Myocardial Infarction

Tomasz Podolecki; Radoslaw Lenarczyk, Jacek Kowalczyk et al. Keywords: ventricular fibrillation, ventricular tachycardia, acute myocardial infarction, percutaneous coronary intervention

ABSTRACT

The aim of the study was to assess the clinical significance of complex ventricular arrhythmias (VAs) (sustained ventricular tachycardia (sVT) and ventricular fibrillation (VF)) in patients with ST-segment elevation myocardial infarction (STEMI) depending on timing of arrhythmia. We analyzed 4, 363 consecutive STEMI-patients treated invasively between 2004 and 2014. The median follow-up was 69.6 months (range: 0–139.8 months). The study population was divided into 2 main groups: VA Group encompassed 476 (10.91 %) patients with VAs, whereas 3887 (89.09 %) subjects without VT/VF were included into the Control Group. Among VA-population, pre-reperfusion VA (34.24%; n=163) was the most common arrhythmia, whereas reperfusion-induced, early post-reperfusion and late post-reperfusion VAs were diagnosed in: 103 (21.64 %), 103 (21.64 %) and 107 (22.48 %) patients, respectively. Every type of sVT/VF complicating STEMI portended significantly worse in-hospital prognosis, however a late onset arrhythmia was associated with the highest (over 5-fold) and reperfusion-induced VA with the lowest (less than 3-fold) increase in mortality risk compared to the Control Group. On the contrary, long-term mortality was significantly increased only in subjects with late post-reperfusion and pre-reperfusion VAs compared to VA-free population (43.93% and 36.81%, respectively vs. 22.58%; p<0.001). Apart from cardiogenic shock on admission, late post-reperfusion (HR 3.39) and pre-reperfusion VAs (HR 2.76) were the strongest independent predictors of death in the analyzed population. In conclusion, one in 10 patients with STEMI treated invasively was affected by sVT/VF. The clinical impact of VAs was strongly dependent on timing of arrhythmia.

>CBS CBS 2019

> CBS 2019 REGISTRATION

> CBS 2019 PROGRAM

> CBS 2019 CALL FOR SCIENCE

> CBS 2019 SPOTLIGHTS

 CBSMD

> CBSMD WEBSITE REGISTRATION

> EDUCATION CENTER

> RECOMMANDED PAPER

> TOP 10 RESEARCH PAPER

> PRE-READING

CBS 2019 CBS 2019 FACULTY Education Resource CBSMD Scientific Library
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top